Navigation Links
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
Date:3/28/2011

BEIJING, March 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its audited financial results for the fourth quarter and full year ended December 31, 2010 before market on Thursday, March 31, 2011.  The Company will host a conference call on Thursday, March 31, 2011 at 8:00 a.m. EDT (March 31, 2011 at 8:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international).  A replay of the call will be available from 11:00 a.m. ET on March 31, 2011 to April 14, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and reference the account number 3055 and the access code 369626.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning March 31, 2011 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For more information, please contact: Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel: +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel: +1-646-536-7025Email: jrando@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Participates in Two Investor Conferences in November
2. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
3. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
4. Sinovac Reports Unaudited First Quarter 2010 Financial Results
5. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
6. Sinovac Announces Upsizing and Pricing of Common Share Offering
7. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
8. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
9. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
10. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
11. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... To acquire information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity ... rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, the ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):